Clal Biotechnology | CBI - Current Liabilities


Clal Biotechnology reported ILS6.66M in Current Liabilities for its fiscal quarter ending in December of 2023.





Current Liabilities Change Date
Arca Biopharma USD 15.37M 5.59M Dec/2025
aTyr Pharma USD 113.19M 97.51M Dec/2025
Bio Path USD 8.68M 819K Sep/2025
Brainstorm Cell Therapeutics USD 11.01M 1.98M Dec/2025
Cara Therapeutics USD 11.04M 362K Sep/2025
Clal Biotechnology ILS 6.66M 3.75M Dec/2023
Compugen USD 22.57M 2.29M Dec/2025
Immunic USD 30.08M 2.77M Sep/2025
Infinity Pharmaceuticals USD 12.06M 775K Jun/2023
Minerva Neurosciences USD 2.29M 381K Dec/2025
RedHill Biopharma USD 22.29M 64K Jun/2025
TherapeuticsMD USD 5.82M 655K Jun/2024